Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 2Genitourinary 2Thoracic 1Lymphoid 1Gynecologic 1Gastrointestinal 1CNS 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Sarcoma 1Recurrence 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Esophageal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 13Gemcitabine 12Cyclophosphamide 10Carboplatin 10Specimen Handling 8Magnetic Resonance Spectroscopy 8Cisplatin 8Docetaxel 7X-Rays 6Filgrastim 6Doxorubicin 6Biopsy 6tislelizumab 5Radiosurgery 5Phantoms, Imaging 5Paclitaxel 5Nivolumab 5Irinotecan 5Bevacizumab 5130-nm albumin-bound paclitaxel 5spartalizumab 4palbociclib 4Thiotepa 4Temozolomide 4Radiotherapy 4Nuclear Medicine Department, Hospital 4Mesna 4Ipilimumab 4Imatinib Mesylate 4Ifosfamide 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma × CLR1404 × Gastrointestinal × Clear all
NCT01495663 2015-02-26

Dose Escalation Study of I-131-CLR1404 in Subjects With Cancer That Does Not Respond to Treatment or Has Returned

Cellectar Biosciences, Inc.

Phase 1 Completed
12 enrolled
BreastGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Recurrence, Sarcoma, Colorectal Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡